Aerska

Aerska develops next-generation RNA interference (RNAi) medicines designed to treat, delay, and prevent diseases of the central nervous system. The company utilizes an antibody-oligonucleotide conjugate platform that combines brain shuttles with systemic administration to transport genetic medicines across the blood-brain barrier. Their approach focuses on precision medicine for neurological disorders like Alzheimer’s disease through biomarker-guided development and patient stratification.